Skye Bioscience Inc. is developing The Conscience Collective to support leaders building successful and sustainable organisations while understanding the wider role of health and healthcare innovation in society.

Public source

Publisher name

Public post

We spend a great deal of time talking about the cost of healthcare. I sometimes wonder whether we spend enough time talking about the value of health. I have believed fo…

Log in to read the full post

Company

Skye Bioscience Inc.

Unlocking new therapeutic pathways for metabolic health

Industry
Biotechnology Research
Location
San Diego, US
Company size
11–50 employees

About Skye Bioscience Inc.

Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

See more

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.

Skye Bioscience Inc. is developing The Conscience Collective to support leaders building successful and sustainable organisations while understanding the wider role of health and healthcare innovation in society. | SeedOps